Oruka Therapeutics
ORKA
95.81
-1.76
-1.80%
Oruka Therapeutics
US · ORKA
#2003 by market cap
Listed 1970
95.81
-1.76
-1.80%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Company notice
Oakridge International Ltd: KS Orka Completes Acquisition of Sokoria Geothermal ProjectN/A · 2017/1/16
-
Rating change
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $130Market Newswire · 2026/9/2
-
Rating change
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fractyl Health, Inc. (GUTS) and Oruka Therapeutics (ORKA)TipRanks · 2026/9/2
-
Company notice
Kaishan Co., Ltd.: The holding company KS Orka Renewables Pte Ltd and PT Optima Nusantara Energi's announcement on joint development of the Simbolon-Samosir geothermal projectSZSI · 2018/3/19
-
Company notice
Kaishan Co., Ltd.: Announcement on the signing of a letter of intent for a joint venture between its wholly-owned subsidiary KS ORKA and a Hungarian partnerSZSI · 2025/11/27
-
Rating change
Wedbush Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $165Market Newswire · 2026/9/24
-
Rating change
Barclays Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $160Market Newswire · 2026/9/21
-
A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $120 to $180Market Newswire · 2026/11/11
-
Piper Sandler Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $180Market Newswire · 2026/10/7
-
A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $120 to $160Market Newswire · 2026/11/10
-
Leerink Partners Maintains Oruka Therapeutics(ORKA.US) With Buy RatingMarket Newswire · 2026/10/28
-
BTIG Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $151Market Newswire · 2026/10/19
-
Rating change
H.C. Wainwright Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $120Market Newswire · 2026/10/27
-
Rating change
A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $120 to $175Market Newswire · 2026/9/24
-
Rating change
LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $175Market Newswire · 2026/9/9
-
Company notice
Kaishan Co., Ltd.: Announcement on KS ORKA Hungary\'s acquisition of exclusive geothermal exploration rights in HungarySZSI · 2025/4/10
-
Rating change
A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $133 to $180Market Newswire · 2026/8/12
-
Company notice
Oakridge International Ltd: KS Orka to Acquire Sokoria Geothermal ProjectN/A · 2016/8/2
-
Rating change
A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $105 to $160Market Newswire · 2026/10/27
-
Rating change
TD Cowen Maintains Oruka Therapeutics(ORKA.US) With Buy RatingMarket Newswire · 2026/8/26
-
Rating change
LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $125Market Newswire · 2026/8/1
-
Rating change
A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $151 to $200Market Newswire · 2026/8/11
-
Rating change
Stifel Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $150Market Newswire · 2026/6/29
-
Rating change
Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), Alto Neuroscience, Inc. (ANRO) and Astrana Health (ASTH)TipRanks · 2026/7/14
-
Rating change
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $100Market Newswire · 2026/6/2
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:27 · For reference only, not investment advice and not tailored to your situation.
Oruka Therapeutics discussion 0 comments